SCHEMBL5865752

SCHEMBL5865752

CCCCOc1ccc2c(c1F)C(F)(F)c1c-2ccc(OCC)c1F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 7/20 0.41
TDP1 Q9NUW8 4/20 0.40
CYP1A2 P05177 3/20 0.40
CYP2C19 P33261 3/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 2/20 0.36
CYP19A1 P11511 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.34
ALDH1A1 P00352 1/20 0.34
MAPT P10636 3/20 0.33
MCHR1 Q99705 1/20 0.33
RAB9A P51151 1/20 0.33
ATM Q13315 1/20 0.33
HPGD P15428 1/20 0.33
FGFR1 P11362 1/20 0.32
FGFR2 P21802 1/20 0.32
CNR1 P21554 1/20 0.32
CNR2 P34972 1/20 0.32
PDK2 Q15119 1/20 0.32
GLA P06280 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10019908 0.91 L3MBTL1 (0.41) L3MBTL1TDP1CYP1A2CYP2C19CYP2D6
SCHEMBL10020000 0.87 L3MBTL1 (0.38) L3MBTL1TDP1CYP1A2CYP2C19CYP2D6
SCHEMBL13870336 0.84 FGFR2 (0.36) L3MBTL1TDP1CYP1A2CYP2C19CYP2D6
SCHEMBL29444864 0.84 L3MBTL1 (0.47) L3MBTL1TDP1CYP1A2CYP2C19CYP2D6
SCHEMBL16855848 0.84 L3MBTL1 (0.47) L3MBTL1TDP1CYP1A2CYP2C19CYP2D6
SCHEMBL15120819 0.83 L3MBTL1 (0.53) L3MBTL1TDP1CYP1A2CYP2C19CYP2D6
SCHEMBL16855833 0.80 CYP1A2 (0.44) L3MBTL1TDP1CYP1A2CYP2C19CYP2D6
SCHEMBL10019990 0.80 CYP2D6 (0.40) L3MBTL1TDP1CYP1A2CYP2C19CYP2D6
SCHEMBL15120786 0.80 CYP1A2 (0.50) L3MBTL1TDP1CYP1A2CYP2C19CYP2D6
SCHEMBL10019998 0.80 L3MBTL1 (0.38) L3MBTL1FGFR1FGFR2CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7087272-B2 negative anisotropy of the dielectric constants; liquid-crystalline media and optical and electro-optical display elements MERCK PATENT GMBH (DE) 2006-08-08 US disclosed
US-20040106798-A1 negative anisotropy of the dielectric constants; liquid-crystalline media and optical and electro-optical display elements MERCK PATENT GMBH (DE) 2004-06-03 US disclosed
EP-1373434-A1 FLUORINATED FLUORENE DERIVATIVES MERCK PATENT GmbH (DE) 2004-01-02 EP disclosed
WO-2002079344-A1 FLUORINATED FLUORENE DERIVATIVES MERCK PATENT GMBH (DE) 2002-10-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040106798-A1 negative anisotropy of the dielectric constants; liquid-crystalline media and optical and electro-optical display elements H1-0, F3, H1-2 L3MBTL1 478/4885TDP1 3533/4885CYP1A2 3731/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.